On the public citation graph

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

https://doi.org/10.1056/nejmoa1808721
0 signed · 291 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2011.1914openalex-snapshot
Bariatric Surgery and Long-term Cardiovascular Events
inferredcites →https://doi.org/10.1001/jama.2012.113905openalex-snapshot
Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories
inferredcites →https://doi.org/10.1001/jama.2016.1558openalex-snapshot
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
inferredcites →https://doi.org/10.1001/jama.2018.3060openalex-snapshot
Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016
inferredcites →https://doi.org/10.1007/s11695-016-2144-xopenalex-snapshot
Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis
inferredcites →https://doi.org/10.1016/j.ahj.2018.03.012openalex-snapshot
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial
inferredcites →https://doi.org/10.1016/j.jacc.2013.11.004openalex-snapshot
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
inferredcites →https://doi.org/10.1016/j.jacc.2016.06.007openalex-snapshot
Cardiovascular Effects of the New Weight Loss Agents
inferredcites →https://doi.org/10.1016/s0140-6736(10)60935-xopenalex-snapshot
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
inferredcites →https://doi.org/10.1038/oby.2012.66openalex-snapshot
Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study
inferredcites →https://doi.org/10.1056/nejm199708283370901openalex-snapshot
Valvular Heart Disease Associated with Fenfluramine–Phentermine
inferredcites →https://doi.org/10.1056/nejmoa066254openalex-snapshot
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
inferredcites →https://doi.org/10.1056/nejmoa0909809openalex-snapshot
Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
inferredcites →https://doi.org/10.1056/nejmoa1003114openalex-snapshot
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
inferredcites →https://doi.org/10.1056/nejmoa1212914openalex-snapshot
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1603827openalex-snapshot
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1614362openalex-snapshot
Health Effects of Overweight and Obesity in 195 Countries over 25 Years
inferredcites →https://doi.org/10.1097/hjh.0000000000000145openalex-snapshot
Cardiovascular effects of phentermine and topiramate
inferredcites →https://doi.org/10.1124/jpet.107.133348openalex-snapshot
Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization
inferredcites →https://doi.org/10.1161/01.cir.0000437739.71477.eeopenalex-snapshot
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
inferredcites →https://doi.org/10.1161/circulationaha.111.023499openalex-snapshot
What Cost Weight Loss?
inferredcites →https://doi.org/10.1161/circulationaha.116.025629openalex-snapshot
Weight Loss and Heart Failure
inferredcites →https://doi.org/10.1172/jci70678openalex-snapshot
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
inferredcites →https://doi.org/10.1210/er.2017-00253openalex-snapshot
The Science of Obesity Management: An Endocrine Society Scientific Statement
inferredcites →https://doi.org/10.1210/jc.2011-1256openalex-snapshot
A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
inferredcites →https://doi.org/10.4103/0976-500x.130158openalex-snapshot
Lorcaserin: A novel antiobesity drug
inferredcites →https://doi.org/10.4158/ep14280.psopenalex-snapshot
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease
inferredcites →https://doi.org/10.7326/0003-4819-155-7-201110040-00006openalex-snapshot
Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4065594openalex-extracted
Bgm, a Newly Synthesized Boron Compound, Induces Apoptosis and Reduces Oxidative Stress by Inhibiting Lipogenesis in 3t3-L1 Adipocytes Via Pparγ and Ctrp3
inferred← citeshttps://doi.org/10.2139/ssrn.5116096openalex-extracted
Outcome Measures for Randomised Clinical Trials and Multicentre Observational Studies of Cardiovascular Diseases Published in Major Clinical Journals: Systematic Review and Evidence Mapping
inferred← citeshttps://doi.org/10.1001/jamainternmed.2023.7862openalex-snapshot
Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.32296openalex-snapshot
Agreement Between Mega-Trials and Smaller Trials
inferred← citeshttps://doi.org/10.1002/14651858.cd007654.pub5openalex-snapshot
Long-term effects of weight-reducing drugs in people with hypertension
inferred← citeshttps://doi.org/10.1002/9781119695257.ch14openalex-snapshot
Cardiovascular Consequences
inferred← citeshttps://doi.org/10.1002/ejhf.3118openalex-snapshot
Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
inferred← citeshttps://doi.org/10.1002/hep.30658openalex-snapshot
Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1002/jcph.2193openalex-snapshot
Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24‐Hour Holter Electrocardiogram Recordings
inferred← citeshttps://doi.org/10.1002/oby.22385openalex-snapshot
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
inferred← citeshttps://doi.org/10.1002/oby.22503openalex-snapshot
Patient Characteristics Associated with Receipt of Prescription Weight‐Management Medications Among Veterans Participating in MOVE!
inferred← citeshttps://doi.org/10.1002/oby.22509openalex-snapshot
Body Fat Distribution and Systolic Blood Pressure in 10,000 Adults with Whole‐Body Imaging: UK Biobank and Oxford BioBank
inferred← citeshttps://doi.org/10.1002/oby.22789openalex-snapshot
Lorcaserin Departs, Leaving More Questions than Answers
inferred← citeshttps://doi.org/10.1002/oby.23086openalex-snapshot
Describing the Weight‐Reduced State: Physiology, Behavior, and Interventions
inferred← citeshttps://doi.org/10.1002/oby.23621openalex-snapshot
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
inferred← citeshttps://doi.org/10.1002/oby.24332openalex-snapshot
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial
inferred← citeshttps://doi.org/10.1002/oby.70211openalex-snapshot
Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015
inferred← citeshttps://doi.org/10.1002/osp4.340openalex-snapshot
Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): a combined subgroup analysis from three randomized, controlled clinical trials
inferred← citeshttps://doi.org/10.1002/osp4.469openalex-snapshot
Safety and efficacy of pharmacologic weight loss in patients with cirrhosis
inferred← citeshttps://doi.org/10.1007/978-3-030-48683-9_11openalex-snapshot
Supportive Component of Treatment: Medications for Treating Obesity
inferred← citeshttps://doi.org/10.1007/978-3-030-56279-3_7openalex-snapshot
Obesity Management and Prevention of Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-78177-4_8openalex-snapshot
Prevention and Treatment of Obesity for Cardiovascular Risk Mitigation: Dietary and Pharmacologic Approaches
inferred← citeshttps://doi.org/10.1007/978-3-030-83399-2_9openalex-snapshot
The Role of Community Pharmacy and Pharmacotherapy in Obesity Management
inferred← citeshttps://doi.org/10.1007/978-3-030-97416-9_112-1openalex-snapshot
Central Modulators of Appetite in Eating Disorders
inferred← citeshttps://doi.org/10.1007/978-3-031-07897-2_2openalex-snapshot
Serotonin
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_23openalex-snapshot
Managing Stable Coronary Artery Disease in Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-26727-7_9openalex-snapshot
General Treatment of Pediatric Obesity
inferred← citeshttps://doi.org/10.1007/978-3-031-46096-8_112openalex-snapshot
Central Modulators of Appetite in Eating Disorders
inferred← citeshttps://doi.org/10.1007/978-3-031-54960-1_13openalex-snapshot
Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction
inferred← citeshttps://doi.org/10.1007/978-3-031-63310-2_2openalex-snapshot
Medical Treatment of Obesity
inferred← citeshttps://doi.org/10.1007/978-3-031-70004-0_3openalex-snapshot
Obesity-Related Comorbidities
inferred← citeshttps://doi.org/10.1007/s00228-021-03160-7openalex-snapshot
Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00702-023-02732-4openalex-snapshot
Current perspectives on brain circuits involved in food addiction-like behaviors
inferred← citeshttps://doi.org/10.1007/s10620-020-06382-4openalex-snapshot
Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1007/s10695-025-01588-7openalex-snapshot
Exemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway
inferred← citeshttps://doi.org/10.1007/s11096-021-01330-2openalex-snapshot
Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020
inferred← citeshttps://doi.org/10.1007/s11298-018-6827-6openalex-snapshot
Warum der Kampf gegen Adipositas oft scheitert
inferred← citeshttps://doi.org/10.1007/s11306-019-1553-yopenalex-snapshot
Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies
inferred← citeshttps://doi.org/10.1007/s11357-025-01519-7openalex-snapshot
5-HT2C agonism as a neurotherapeutic for sarcopenia: preclinical proof of concept
inferred← citeshttps://doi.org/10.1007/s11428-019-0486-4openalex-snapshot
Epidemiologie, Prävention und Therapie der Adipositas
inferred← citeshttps://doi.org/10.1007/s11695-019-04206-7openalex-snapshot
Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery
inferred← citeshttps://doi.org/10.1007/s11886-023-02016-zopenalex-snapshot
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
inferred← citeshttps://doi.org/10.1007/s11906-019-0915-1openalex-snapshot
Weight Loss Medications in the Treatment of Obesity and Hypertension
inferred← citeshttps://doi.org/10.1007/s11920-025-01601-zopenalex-snapshot
Sex Differences in Obesity and Its Treatment
inferred← citeshttps://doi.org/10.1007/s11930-020-00287-zopenalex-snapshot
Treatment of Delayed Ejaculation
inferred← citeshttps://doi.org/10.1007/s12011-022-03261-zopenalex-snapshot
BGM, a Newly Synthesised Boron Compound, Induces Apoptosis and Reduces Oxidative Stress by Inhibiting Lipogenesis in 3T3-L1 Adipocytes via PPARγ and CTRP3
inferred← citeshttps://doi.org/10.1007/s12020-025-04528-wopenalex-snapshot
Anti-obesity drugs: comprehensive review and emerging therapies
inferred← citeshttps://doi.org/10.1007/s12325-019-00962-1openalex-snapshot
Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials
inferred← citeshttps://doi.org/10.1007/s12471-021-01585-4openalex-snapshot
Novel advances in cardiac rehabilitation
inferred← citeshttps://doi.org/10.1007/s13410-020-00819-2openalex-snapshot
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
inferred← citeshttps://doi.org/10.1007/s13679-020-00378-xopenalex-snapshot
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
inferred← citeshttps://doi.org/10.1007/s15027-018-1400-5openalex-snapshot
Erstmals bewiesen: eine Abnehmpille ist kardiovaskulär sicher
inferred← citeshttps://doi.org/10.1007/s15034-018-1416-zopenalex-snapshot
Appetitzügler verringert Diabetesinzidenz
inferred← citeshttps://doi.org/10.1007/s40256-019-00336-6openalex-snapshot
Evidence-Based Cardiovascular Risk Management in Diabetes
inferred← citeshttps://doi.org/10.1007/s40256-020-00428-8openalex-snapshot
Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s40263-022-00896-3openalex-snapshot
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
inferred← citeshttps://doi.org/10.1007/s40264-019-00812-7openalex-snapshot
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
inferred← citeshttps://doi.org/10.1007/s40267-020-00714-0openalex-snapshot
Manage cardiovascular risk in patients with type 2 diabetes by using agents with proven cardiovascular benefits
inferred← citeshttps://doi.org/10.1007/s40278-018-51350-yopenalex-snapshot
Lorcaserin: no increased risk of cardiovascular events
inferred← citeshttps://doi.org/10.1016/b978-0-12-815290-4.00016-6openalex-snapshot
Weight loss: Lifestyle interventions and pharmacotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-87862-3.00015-xopenalex-snapshot
Prevention of Heart Failure in People With Diabetes
inferred← citeshttps://doi.org/10.1016/b978-0-323-99991-5.00018-8openalex-snapshot
The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches
inferred← citeshttps://doi.org/10.1016/b978-0-443-27370-4.00013-5openalex-snapshot
Pharmacological targets in obesity
inferred← citeshttps://doi.org/10.1016/b978-84-9113-949-2.00007-xopenalex-snapshot
10.1016/b978-84-9113-949-2.00007-x
inferred← citeshttps://doi.org/10.1016/j.ajpc.2021.100250openalex-snapshot
Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement
inferred← citeshttps://doi.org/10.1016/j.amepre.2020.01.018openalex-snapshot
Prevalence and Management of Adult Obesity in a Large U.S. Academic Health System
inferred← citeshttps://doi.org/10.1016/j.annepidem.2025.10.012openalex-snapshot
Application of machine learning and deep learning approaches for prediction modeling with time-to-event outcomes in clinical epidemiology. Methods comparison and practical considerations for generalizability and interpretability
inferred← citeshttps://doi.org/10.1016/j.arr.2025.102727openalex-snapshot
RETRACTED: Prevention of cardiovascular disease for healthy aging and longevity: A new scoring system and related “mechanisms-hallmarks-biomarkers”
inferred← citeshttps://doi.org/10.1016/j.bioorg.2021.105380openalex-snapshot
Amberlyst-15 catalysed synthesis of novel indole derivatives under ultrasound irradiation: Their evaluation as serotonin 5-HT2C receptor agonists
inferred← citeshttps://doi.org/10.1016/j.bioorg.2022.106202openalex-snapshot
Sonochemical synthesis and biological evaluation of isoquinolin-1(2H)-one/isoindolin-1-one derivatives: Discovery of a positive ago-allosteric modulator (PAAM) of 5HT2CR
inferred← citeshttps://doi.org/10.1016/j.bmcl.2021.127872openalex-snapshot
Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT2C receptor
inferred← citeshttps://doi.org/10.1016/j.cardfail.2019.03.007openalex-snapshot
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee
inferred← citeshttps://doi.org/10.1016/j.cardfail.2020.01.021openalex-snapshot
Body Fat and Fitness for Ventricular Assist Device Therapy
inferred← citeshttps://doi.org/10.1016/j.cmet.2018.09.016openalex-snapshot
Distinct Hypothalamic and Brainstem Contributions to Lorcaserin Action
inferred← citeshttps://doi.org/10.1016/j.cophys.2019.04.017openalex-snapshot
Pharmaceutical approaches to weight management: behavioural mechanisms of action
inferred← citeshttps://doi.org/10.1016/j.ecl.2020.02.007openalex-snapshot
Barriers and Solutions for Prescribing Obesity Pharmacotherapy
inferred← citeshttps://doi.org/10.1016/j.ecl.2021.05.004openalex-snapshot
Prevention of Diabetes Macrovascular Complications and Heart Failure
inferred← citeshttps://doi.org/10.1016/j.hrtlng.2025.07.009openalex-snapshot
Cardiometabolic effects of GLP-1 analogs in obese and overweight patients with preexisting cardiovascular disease: A systematic review and meta analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.ijcard.2022.11.010openalex-snapshot
Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007–2016
inferred← citeshttps://doi.org/10.1016/j.ijcrp.2025.200466openalex-snapshot
Risk factors of acute coronary syndrome among patients admitted to cardiac care units at governmental hospitals in the Gaza Strip: Case- control study
inferred← citeshttps://doi.org/10.1016/j.jacc.2019.11.046openalex-snapshot
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
inferred← citeshttps://doi.org/10.1016/j.jacc.2021.05.035openalex-snapshot
Management of Obesity in Cardiovascular Practice
inferred← citeshttps://doi.org/10.1016/j.jacc.2023.04.031openalex-snapshot
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1016/j.jacc.2023.04.032openalex-snapshot
An Atherothrombotic Risk Score for Patients With Diabetes
inferred← citeshttps://doi.org/10.1016/j.jacc.2024.08.007openalex-snapshot
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
inferred← citeshttps://doi.org/10.1016/j.jacc.2026.01.013openalex-snapshot
Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines
inferred← citeshttps://doi.org/10.1016/j.jchf.2025.102780openalex-snapshot
Survodutide for the Treatment of Obesity
inferred← citeshttps://doi.org/10.1016/j.jconrel.2024.09.025openalex-snapshot
Enhanced browning of adipose tissue by mirabegron-microspheres
inferred← citeshttps://doi.org/10.1016/j.jnma.2024.09.004openalex-snapshot
Updates in pharmacotherapy of obesity
inferred← citeshttps://doi.org/10.1016/j.jsxm.2020.02.027openalex-snapshot
Lorcaserin Administration has Pro-Ejaculatory Effects in Rats via 5-HT2C Receptors Activation: A Putative Pharmacologic Strategy to Delayed Ejaculation?
inferred← citeshttps://doi.org/10.1016/j.jtcme.2023.08.004openalex-snapshot
Phytoformulation with hydroxycitric acid and capsaicin protects against high-fat-diet-induced obesity cardiomyopathy by reducing cardiac lipid deposition and ameliorating inflammation and apoptosis in the heart
inferred← citeshttps://doi.org/10.1016/j.lfs.2024.123171openalex-snapshot
The 5-HT-related gut-brain axis in obesity
inferred← citeshttps://doi.org/10.1016/j.mayocpiqo.2022.01.004openalex-snapshot
Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial
inferred← citeshttps://doi.org/10.1016/j.metabol.2018.10.010openalex-snapshot
Pharmacotherapy of obesity: Available medications and drugs under investigation
inferred← citeshttps://doi.org/10.1016/j.metabol.2018.10.011openalex-snapshot
Obesity and cardiovascular disease: revisiting an old relationship
inferred← citeshttps://doi.org/10.1016/j.metabol.2018.12.012openalex-snapshot
The pathogenesis of obesity
inferred← citeshttps://doi.org/10.1016/j.metabol.2024.156099openalex-snapshot
Serotonin neurons integrate GABA and dopamine inputs to regulate meal initiation
inferred← citeshttps://doi.org/10.1016/j.numecd.2021.05.023openalex-snapshot
Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity
inferred← citeshttps://doi.org/10.1016/j.nupar.2022.09.001openalex-snapshot
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
inferred← citeshttps://doi.org/10.1016/j.obpill.2023.100071openalex-snapshot
A review of the evidence on cardiovascular outcomes from obesity treatment
inferred← citeshttps://doi.org/10.1016/j.obpill.2025.100169openalex-snapshot
Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice
inferred← citeshttps://doi.org/10.1016/j.obpill.2026.100280openalex-snapshot
Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion
inferred← citeshttps://doi.org/10.1016/j.orcp.2019.03.007openalex-snapshot
Attitudes and perceptions of the general public on obesity and its treatment options in Singapore
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2019.107417openalex-snapshot
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
inferred← citeshttps://doi.org/10.1016/j.phrs.2021.105649openalex-snapshot
Pharmacotherapy of obesity: An update
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.108080openalex-snapshot
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
inferred← citeshttps://doi.org/10.1016/j.rccl.2019.01.007openalex-snapshot
Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
inferred← citeshttps://doi.org/10.1016/j.semerg.2019.04.005openalex-snapshot
Tratamiento farmacológico de la obesidad para médicos de Atención Primaria
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2021.06.002openalex-snapshot
The Renal Pathology of Obesity: Structure-Function Correlations
inferred← citeshttps://doi.org/10.1016/s0140-6736(18)32328-6openalex-snapshot
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
inferred← citeshttps://doi.org/10.1016/s0140-6736(18)32460-7openalex-snapshot
Lorcaserin: balancing efficacy with potential risks
inferred← citeshttps://doi.org/10.1016/s0140-6736(20)32234-0openalex-snapshot
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
inferred← citeshttps://doi.org/10.1016/s2213-8587(24)00098-6openalex-snapshot
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review
inferred← citeshttps://doi.org/10.1038/s41366-020-0544-4openalex-snapshot
The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database
inferred← citeshttps://doi.org/10.1038/s41367-020-0015-3openalex-snapshot
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?
inferred← citeshttps://doi.org/10.1038/s41392-022-01149-xopenalex-snapshot
Signaling pathways in obesity: mechanisms and therapeutic interventions
inferred← citeshttps://doi.org/10.1038/s41569-018-0092-yopenalex-snapshot
Cardiovascular safety of lorcaserin
inferred← citeshttps://doi.org/10.1038/s41569-020-00465-5openalex-snapshot
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
inferred← citeshttps://doi.org/10.1038/s41571-018-0089-9openalex-snapshot
Progress in adjuvant systemic therapy for breast cancer
inferred← citeshttps://doi.org/10.1038/s41574-018-0109-yopenalex-snapshot
How does lorcaserin facilitate weight loss and who will benefit?
inferred← citeshttps://doi.org/10.1038/s41598-019-49347-yopenalex-snapshot
Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146
inferred← citeshttps://doi.org/10.1039/d0fo02600jopenalex-snapshot
Polysaccharides from fermented Momordica charantia L. with Lactobacillus plantarum NCU116 ameliorate metabolic disorders and gut microbiota change in obese rats
inferred← citeshttps://doi.org/10.1055/a-1118-2562openalex-snapshot
Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas
inferred← citeshttps://doi.org/10.1056/nejmc1813971openalex-snapshot
Lorcaserin Safety in Overweight or Obese Patients
inferred← citeshttps://doi.org/10.1056/nejme1810855openalex-snapshot
Lorcaserin — Elixir or Liability?
inferred← citeshttps://doi.org/10.1056/nejmoa2215025openalex-snapshot
Cardiovascular Safety of Testosterone-Replacement Therapy
inferred← citeshttps://doi.org/10.1056/nejmoa2307563openalex-snapshot
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
inferred← citeshttps://doi.org/10.1056/nejmp2003873openalex-snapshot
Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
inferred← citeshttps://doi.org/10.1080/03630242.2022.2066747openalex-snapshot
Obesity, weight loss and gynecologic neoplasms: a narrative review
inferred← citeshttps://doi.org/10.1080/07853890.2023.2203517openalex-snapshot
Recent advances in the treatment of patients with obesity and chronic kidney disease
inferred← citeshttps://doi.org/10.1080/13813455.2021.1874017openalex-snapshot
Biochanin A attenuates obesity cardiomyopathy in rats by inhibiting oxidative stress and inflammation through the Nrf-2 pathway
inferred← citeshttps://doi.org/10.1080/14656566.2018.1561867openalex-snapshot
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
inferred← citeshttps://doi.org/10.1080/14656566.2019.1685496openalex-snapshot
An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity
inferred← citeshttps://doi.org/10.1080/14656566.2019.1695779openalex-snapshot
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
inferred← citeshttps://doi.org/10.1080/14656566.2020.1858795openalex-snapshot
Has the bloom gone out of lorcaserin following the CAMELLIA-TIMI61 trial?
inferred← citeshttps://doi.org/10.1080/14659891.2023.2202760openalex-snapshot
Open-label pilot of lorcaserin (a serotonin 2C-receptor agonist) for cannabis use disorder
inferred← citeshttps://doi.org/10.1080/14740338.2020.1806234openalex-snapshot
The risk of cardiovascular complications with current obesity drugs
inferred← citeshttps://doi.org/10.1080/17425255.2019.1667334openalex-snapshot
Drug-drug interactions when treating HIV-related metabolic disorders
inferred← citeshttps://doi.org/10.1080/17446651.2023.2209176openalex-snapshot
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
inferred← citeshttps://doi.org/10.1080/17460441.2019.1646243openalex-snapshot
Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
inferred← citeshttps://doi.org/10.1080/17512433.2020.1698291openalex-snapshot
Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
inferred← citeshttps://doi.org/10.1080/17512433.2020.1703109openalex-snapshot
Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1093/aje/kwaf226openalex-snapshot
Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials
inferred← citeshttps://doi.org/10.1093/ehjqcco/qcae063openalex-snapshot
The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes
inferred← citeshttps://doi.org/10.1093/eurheartj/ehy894openalex-snapshot
The year in cardiology 2018: prevention
inferred← citeshttps://doi.org/10.1093/eurjpc/zwad280openalex-snapshot
Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
inferred← citeshttps://doi.org/10.1093/fampra/cmac141openalex-snapshot
Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting
inferred← citeshttps://doi.org/10.1093/jncimonographs/lgad003openalex-snapshot
Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities
inferred← citeshttps://doi.org/10.1093/lifemeta/loae039openalex-snapshot
Serotonin signaling to regulate energy metabolism: a gut microbiota perspective
inferred← citeshttps://doi.org/10.1093/med/9780198865278.003.0007openalex-snapshot
Defining Your Shape
inferred← citeshttps://doi.org/10.1093/med/9780198870197.003.0225openalex-snapshot
Dietary and Medical Management of Obesity
inferred← citeshttps://doi.org/10.1097/cp9.0000000000000114openalex-snapshot
Cardiovascular effects of anti-obesity medications: the perils and promise
inferred← citeshttps://doi.org/10.1097/ede.0000000000001393openalex-snapshot
Weight Change and the Onset of Cardiovascular Diseases: Emulating Trials Using Electronic Health Records
inferred← citeshttps://doi.org/10.1097/gme.0000000000001599openalex-snapshot
A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study
inferred← citeshttps://doi.org/10.1097/hco.0000000000000959openalex-snapshot
Team-based strategies to prevent heart failure
inferred← citeshttps://doi.org/10.1097/jcma.0000000000001263openalex-snapshot
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
inferred← citeshttps://doi.org/10.1101/2024.05.09.24307122openalex-snapshot
Agreement between mega-trials and smaller trials: a meta-research study
inferred← citeshttps://doi.org/10.1111/apt.15721openalex-snapshot
Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications
inferred← citeshttps://doi.org/10.1111/cen.14625openalex-snapshot
Childhood obesity: A review of current and future management options
inferred← citeshttps://doi.org/10.1111/ctr.14187openalex-snapshot
Weight gain post–heart transplantation is associated with an increased risk for allograft vasculopathy and rejection
inferred← citeshttps://doi.org/10.1111/dom.13655openalex-snapshot
Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial
inferred← citeshttps://doi.org/10.1111/dom.13661openalex-snapshot
Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults
inferred← citeshttps://doi.org/10.1111/dom.14367openalex-snapshot
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States
inferred← citeshttps://doi.org/10.1111/dom.15062openalex-snapshot
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
inferred← citeshttps://doi.org/10.1111/dom.15798openalex-snapshot
Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
inferred← citeshttps://doi.org/10.1111/dom.70496openalex-snapshot
Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial
inferred← citeshttps://doi.org/10.1111/epi.17376openalex-snapshot
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVI ): II . Drugs in more advanced clinical development
inferred← citeshttps://doi.org/10.1111/jcpt.13047openalex-snapshot
Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/jne.12960openalex-snapshot
Role of serotonin in body weight, insulin secretion and glycaemic control
inferred← citeshttps://doi.org/10.1111/obr.13112openalex-snapshot
Cardiovascular outcome trials in obesity: A review
inferred← citeshttps://doi.org/10.1111/obr.13170openalex-snapshot
Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/obr.13210openalex-snapshot
Serotonin, food intake, and obesity
inferred← citeshttps://doi.org/10.1111/obr.13521openalex-snapshot
Two‐sided roles of adipose tissue: Rethinking the obesity paradox in various human diseases from a new perspective
inferred← citeshttps://doi.org/10.1111/obr.70204openalex-snapshot
Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond
inferred← citeshttps://doi.org/10.1136/bmj.l464openalex-snapshot
Acclaimed anti-obesity drug fails to impress scouts for clinically important research
inferred← citeshttps://doi.org/10.1136/bmjebm-2018-111128openalex-snapshot
Lorcaserin in obesity: minimal benefits and ill-defined harms
inferred← citeshttps://doi.org/10.1136/bmjopen-2019-029426openalex-snapshot
Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1136/heartjnl-2018-314551openalex-snapshot
The sEROtonergic pathway: a hERO for the brain, a zERO for the valves?
inferred← citeshttps://doi.org/10.1152/physrev.00023.2021openalex-snapshot
A primer on obesity-related cardiomyopathy
inferred← citeshttps://doi.org/10.1155/ijcp/1108381openalex-snapshot
Nonlinear Association Between Serum Klotho Concentration and All‐Cause Mortality in Patients With Heart Failure
inferred← citeshttps://doi.org/10.1159/000504546openalex-snapshot
Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern
inferred← citeshttps://doi.org/10.1161/cir.0000000000000766openalex-snapshot
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
inferred← citeshttps://doi.org/10.1161/circresaha.119.315897openalex-snapshot
Treatment of Obesity in Mitigating Metabolic Risk
inferred← citeshttps://doi.org/10.1161/circulationaha.118.038341openalex-snapshot
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial
inferred← citeshttps://doi.org/10.1161/circulationaha.118.038677openalex-snapshot
Trials and Tribulations in Studying Kidney Outcomes With Intentional Weight Loss
inferred← citeshttps://doi.org/10.1161/circulationaha.119.044865openalex-snapshot
Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1161/circulationaha.120.050941openalex-snapshot
Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1161/circulationaha.120.052339openalex-snapshot
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials
inferred← citeshttps://doi.org/10.1161/hypertensionaha.118.11676openalex-snapshot
Obesity-Associated Organ Damage and Sympathetic Nervous Activity
inferred← citeshttps://doi.org/10.1161/jaha.122.029282openalex-snapshot
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
inferred← citeshttps://doi.org/10.11648/j.ccr.20190303.14openalex-snapshot
Treating the Brain But Forgetting the Heart: Mitral Valvular Disease Cabergoline Induced
inferred← citeshttps://doi.org/10.1172/jci145331openalex-snapshot
Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity-related insulin resistance
inferred← citeshttps://doi.org/10.1177/02698811231190865openalex-snapshot
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
inferred← citeshttps://doi.org/10.1177/2042018819834869openalex-snapshot
Diabetic cardiomyopathy: prevalence, determinants and potential treatments
inferred← citeshttps://doi.org/10.1177/2042018820918789openalex-snapshot
Medications for the treatment of obesity in adolescents
inferred← citeshttps://doi.org/10.1186/s12902-018-0317-4openalex-snapshot
Cardiovascular risk reduction over time in patients with diabetes or pre-diabetes undergoing bariatric surgery: data from a single-center retrospective observational study
inferred← citeshttps://doi.org/10.1186/s12958-019-0530-7openalex-snapshot
Proteomic alterations underlie an association with teratozoospermia in obese mice sperm
inferred← citeshttps://doi.org/10.1186/s13063-021-05954-7openalex-snapshot
PATHWEIGH, pragmatic weight management in adult patients in primary care in Colorado, USA: study protocol for a stepped wedge cluster randomized trial
inferred← citeshttps://doi.org/10.1186/s13098-019-0468-0openalex-snapshot
Cardiovascular risk and obesity
inferred← citeshttps://doi.org/10.1186/s13578-023-01091-7openalex-snapshot
Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review
showing the first 200 of 263 · page through all 263
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.